1333400-85-3

Upstream product

• 7697-26-9 3-bromo-4-methylbenzoic acid 
• 104901-43-1 methyl 3-bromo-4-methylbenzoate 
• 51779-32-9 iminodicarboxylic acid di-tert-butyl ester 
• 78946-25-5 3-bromo-4-(bromomethyl)benzoic acid methyl ester 

Downstream Products

• 1333400-84-2 3-bromo-4-(tert-butoxycarbonylamino-methyl)benzoic acid 
• 1333400-86-4 3-bromo-4-(tert-butoxycarbonylamino-methyl)benzoic acid methyl ester 
• 1333400-87-5 [2-bromo-4-(pyridin-4-ylcarbamoyl)-benzyl]-carbamic acid tert-butyl ester 
• 1333400-45-5 C₂₆H₂₆FN₃O₄ 
• 1333400-46-6 tetrahydrofuran-2-ylmethyl 2'-(aminomethyl)-5'-{[(3-fluoropyridin-4-yl)amino]carbonyl} biphenyl-3-carboxylate 
• 1333400-47-7 C₂₄H₂₂FN₃O₃ 
• 1333400-24-0 C₂₅H₂₄FN₃O₃ 
• 1333400-25-1 C₂₆H₂₆FN₃O₃ 
• 1333398-79-0 2'-aminomethyl-5'-(pyridin-4-ylcarbamoyl)-biphenyl-3-carboxylic acid cyclohexyl methyl ester 
• 1333398-78-9 2'-aminomethyl-5'-(pyridin-4-ylcarbamoyl)-biphenyl-3-carboxylic acid cyclopentylmethyl ester 
• 1333400-15-9 C₂₆H₂₀FN₃O₃ 

Relevant academic research and scientific papers

3-[2-(Aminomethyl)-5-[(pyridin-4-yl)carbamoyl]phenyl] benzoates as soft ROCK inhibitors

Clinical development of ROCK inhibitors has so far been limited by systemic or local ROCK-associated side effects. A soft drug approach, which involves predictable metabolic inactivation of an active compound to a nontoxic metabolite, could represent an a

HETEROCYCLIC AMIDES AS ROCK INHIBITORS

The present invention relates to new kinase inhibitors of formula (I), more specifically ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In particular, the present invention relates to new ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In addition, the invention relates to methods of treatment and use of said compounds in the manufacture of a medicament for the application to a number of therapeutic indications including sexual dysfunction, inflammatory diseases, ophthalmic diseases and Respiratory diseases.